Publication
Article
Generic Product News for November 2020.
PREDNISONE TABLETS, 1 MG
MARKETED BY: Strides Pharma Inc
COMPARE TO: Meticorten
The FDA recently approved Strides Pharma Sciences’s generic prednisone tablets in a dosage strength of 1 mg, used to treat allergic disorders, arthritis, breathing disorders, colitis, lupus, psoriasis, skin conditions, and ulcerative colitis. As a corticosteroid, prednisone tablets decrease the immune system’s response to various diseases to reduce symptoms, such as allergic-type reactions and swelling. Adverse effects can include loss of appetite, nausea, and vomiting.
FOR MORE INFORMATION: strides.com
ICOSAPENT ETHYL, 1 G
MARKETED BY: Hikma Pharmaceuticals USA Inc
COMPARE TO: Vascepa
After its FDA approval in May 2020, the US Court of Appeals for the Federal Circuit upheld a ruling finding that Hikma Pharmaceuticals’ generic icosapent ethyl does not infringe on any Amarin-owned patents, and Hikma is working toward launch. The drug is indicated as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Icosapent ethyl is a type of omega-3 fatty acid, thought to work by decreasing the amount of triglycerides made by the body. Vascepa had a market value of about $1.1 billion in the 12 months ended July 2020, according to IQVIA.
FOR MORE INFORMATION: hikma.com
NIZATIDINE ORAL SOLUTION, 15 MG/ML
MARKETED BY: Amneal Pharmaceuticals
COMPARE TO: Axid
Amneal Pharmaceuticals offers the only oral liquid form of nizatidine available in the United States, indicated for the short-term treatment and maintenance therapy of ulcers and for the treatment of esophagitis and associated heartburn related to gastroesophageal reflux disease. A statement from the company said that its offering is in response to dwindling nazitidine treatment options. It is available as a peppermint-flavored liquid sold in 480-mL bottles.
FOR MORE INFORMATION: amneal.com
AZACITIDINE FOR INJECTION, 100 MG
MARKETED BY: Hikma Pharmaceuticals USA Inc
COMPARE TO: Vidaza
Hikma Pharmaceuticals is introducing azacitidine for injection, available in a dosage strength of 100 mg. The drug is indicated for the treatment of patients with several subtypes of French-American-British myelodysplastic syndrome, including chronic myelomonocytic leukemia, refractory anemia with excess blasts or with excess blasts in transformation, and chronic myelomonocytic leukemia. Azacitidine for injection had a market value of about $82 million in the 12 months ended July 2020, according to data from IQVIA.
FOR MORE INFORMATION: hikma.com